Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Sub Category
Metastatic Breast
Study Name
POL6326-009: An International, Phase 3, Muticenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
Principal Investigator
Gordan Srkalovic
Study Information
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance